MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ironwood Pharmaceuticals Inc

Abierto

SectorSanidad

0.87 3.57

Resumen

Variación precio

24h

Actual

Mínimo

0.8

Máximo

0.89

Métricas clave

By Trading Economics

Ingresos

-1.4M

2.3M

Ventas

-1M

91M

P/B

Media del Sector

70.49

57.333

BPA

0.02

Margen de beneficios

2.492

Empleados

253

EBITDA

6.1M

33M

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-249M

118M

Apertura anterior

-2.7

Cierre anterior

0.87

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Ironwood Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 abr 2025, 14:26 UTC

Principales Movimientos del Mercado

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Comparación entre iguales

Cambio de precio

Ironwood Pharmaceuticals Inc previsión

Consenso

By TipRanks

Neutral

6 ratings

0

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.7222 / 0.9055Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.